In depth analysis and discussion on the significance of the results and its implications on the future of Renal Denervation
Combatting the world’s largest silent killer. This four part documentary series explores the history, the trials and tribulations, the renewed success and the future of Renal Denervation.
The series begins with a reminder of the scale of hypertension, and historically, how we have struggled to diagnose, treat and combat the world’s largest silent killer. We introduce the biological hypothesis of RDN - as a potential solution to reducing these deaths, difficulties and risks; a glimmer of hope in the complex story of hypertension.
The early RDN trials, HTN 1 & HTN 2, showed promising signs of success. However, another trial had to be conducted before getting full FDA approval, HTN 3.
The results of the HTN 3 trial were a disappointment to the community. And in this episode, we find out why. What had changed since the first trials? How did these neutral results affect the community’s opinion of RDN?